Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6CD7

Crystal structure of APH(2")-IVa in complex with plazomicin

Replaces:  6C0C
Summary for 6CD7
Entry DOI10.2210/pdb6cd7/pdb
DescriptorAPH(2'')-Id, CHLORIDE ION, (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-{[(2S,3R)-3-amino-6-{[(2-hydroxyethyl)amino]methyl}-3,4-dihydro-2H-pyran-2-y l]oxy}-2-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-3-hydroxycyclohexyl]-2-hydroxybutanamide, ... (4 entities in total)
Functional Keywordsstructural genomics, center for structural genomics of infectious diseases, csgid, eukaryotic protein kinase-like fold, aminoglycoside phosphotransferase, kinase, transferase, aminoglycosides, plazomicin, antibiotic, transferase-antibiotic complex, transferase/antibiotic
Biological sourceEnterococcus casseliflavus (Enterococcus flavescens)
Total number of polymer chains2
Total formula weight71699.42
Authors
Stogios, P.J.,Evdokimova, E.,Dong, A.,Di Leo, R.,Savchenko, A.,Satchell, K.J.,Joachimiak, J.,Center for Structural Genomics of Infectious Diseases (CSGID) (deposition date: 2018-02-08, release date: 2018-02-28, Last modification date: 2023-10-04)
Primary citationCox, G.,Ejim, L.,Stogios, P.J.,Koteva, K.,Bordeleau, E.,Evdokimova, E.,Sieron, A.O.,Savchenko, A.,Serio, A.W.,Krause, K.M.,Wright, G.D.
Plazomicin Retains Antibiotic Activity against Most Aminoglycoside Modifying Enzymes.
ACS Infect Dis, 4:980-987, 2018
Cited by
PubMed Abstract: Plazomicin is a next-generation, semisynthetic aminoglycoside antibiotic currently under development for the treatment of infections due to multidrug-resistant Enterobacteriaceae. The compound was designed by chemical modification of the natural product sisomicin to provide protection from common aminoglycoside modifying enzymes that chemically alter these drugs via N-acetylation, O-adenylylation, or O-phosphorylation. In this study, plazomicin was profiled against a panel of isogenic strains of Escherichia coli individually expressing twenty-one aminoglycoside resistance enzymes. Plazomicin retained antibacterial activity against 15 of the 17 modifying enzyme-expressing strains tested. Expression of only two of the modifying enzymes, aac(2')-Ia and aph(2″)-IVa, decreased plazomicin potency. On the other hand, expression of 16S rRNA ribosomal methyltransferases results in a complete lack of plazomicin potency. In vitro enzymatic assessment confirmed that AAC(2')-Ia and APH(2'')-IVa (aminoglycoside acetyltransferase, AAC; aminoglycoside phosphotransferase, APH) were able to utilize plazomicin as a substrate. AAC(2')-Ia and APH(2'')-IVa are limited in their distribution to Providencia stuartii and Enterococci, respectively. These data demonstrate that plazomicin is not modified by a broad spectrum of common aminoglycoside modifying enzymes including those commonly found in Enterobacteriaceae. However, plazomicin is inactive in the presence of 16S rRNA ribosomal methyltransferases, which should be monitored in future surveillance programs.
PubMed: 29634241
DOI: 10.1021/acsinfecdis.8b00001
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.53 Å)
Structure validation

227111

건을2024-11-06부터공개중

PDB statisticsPDBj update infoContact PDBjnumon